Loading
Sequencing the unique genetic barcode of a patient's leukaemia to find one cancer cell in a million.
clonoSEQ (Adaptive Biotechnologies) tracks clonal IGH/TCR rearrangements at 10^-6 and is FDA-cleared for ALL, myeloma, and CLL. In AML, quantitative PCR of NPM1 or core-binding-factor fusion transcripts and error-corrected NGS of persistent mutations (excluding DNMT3A/TET2/ASXL1) define molecular MRD per ELN 2021. MRD status now drives transplant decisions in AML, blinatumomab use in ALL, and fixed-duration versus continuous therapy debates in CLL.
The assay deep-sequences a patient-specific clonotype or mutation with error correction.
A DNA test that counts leftover leukaemia, myeloma or lymphoma cells down to one in a million, used to decide whether treatment has really worked.
Query for this technology: (TITLE:"NGS-based MRD" OR ABSTRACT:"NGS-based MRD" OR TITLE:"clonoSEQ and molecular MRD" OR ABSTRACT:"clonoSEQ and molecular MRD") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NGS-based MRD (clonoSEQ and molecular MRD), not a curated reading list.
Shares Residual disease kinetics (BCR-ABL halving and ctDNA slopes), Immunoglobulin and T-cell receptor clonality, B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status), Immunoglobulin and T-cell receptor clonality testing.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Mantle cell lymphoma, Chronic lymphocytic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Mantle cell lymphoma, Chronic lymphocytic leukaemia.
Shares MRD-guided transplant decisions in intermediate-risk AML, FLT3-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Myelodysplastic syndromes / neoplasms (MDS).
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Mantle cell lymphoma, Chronic lymphocytic leukaemia.
Shares clonoSEQ, Newly diagnosed multiple myeloma, transplant-ineligible, Newly diagnosed multiple myeloma, transplant-eligible, Dormant cells and minimal residual disease.
Shares B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status), Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL), Standard-risk B-cell acute lymphoblastic leukaemia in children, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
Shares MRD-guided transplant decisions in intermediate-risk AML, Transplant-free Ph-positive ALL for MRD-negative adults, MRD-negative complete remission, Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL).